Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 27;108(4):898–910. doi: 10.1097/TP.0000000000004877

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

FIGURE 3. — Measured dd-cfDNA (cp/mL) in MMDx subgroups (A), rejection archetypes (B), injury archetypes (C), and injury archetypes without MMDx rejection (D). Plasma dd-cfDNA varied significantly across MMDx subgroups, rejection archetypes, injury archetypes, and injury archetypes without MMDx rejection. Colored circles represent dd-cfDNA results for individual biopsies. Gray boxes represent the interquartile range, with whiskers representing 1.5× the interquartile range. Median and geometric mean values for each subgroup/archetype are represented by horizontal black and red bars, respectively. Lettering display above each subgroup/archetype represents post-hoc test results among groups. Groups/archetypes sharing the same letter, within each panel, are not significantly different from one another. AMR, antibody-mediated rejection; cAKI, clinical acute kidney injury; CKD, chronic kidney disease; dd-cfDNA, donor-derived cell-free DNA; EAMR, early-stage AMR; FAMR, fully-developed AMR; LAMR, late-stage AMR; mAKI, molecular acute kidney injury; MMDx, Molecular Microscope Diagnostic System; NR, no rejection; NRNI, MMDx Normal and archetypal No injury; pAMR, possible AMR; pTCMR, possible TCMR; TCMR, T cell–mediated rejection.